Last updated: September 4, 2026
Perfluorohexyloctane, marketed as Miebo by Bausch + Lomb, is an ophthalmic therapy for the signs and symptoms of dry eye disease associated with meibomian gland dysfunction. FDA approval in October 2023 created a new prescription category based on tear-film evaporation reduction rather than aqueous tear stimulation or anti-inflammatory activity.
Miebo’s commercial trajectory depends on four factors: conversion of diagnosed dry-eye patients from established therapies, payer coverage, physician adoption of meibomian gland dysfunction as a treatment target, and the duration of Bausch + Lomb’s regulatory and patent protection. The product has significant expansion potential in the large dry-eye market, but its uptake faces competition from Restasis, Xiidra, Tyrvaya, generic cyclosporine products, lifitegrast, punctal procedures and over-the-counter lubricants.
What is perfluorohexyloctane and how does Miebo work?
Perfluorohexyloctane is a semifluorinated alkane formulated as an ophthalmic solution. Miebo is administered as one drop in each affected eye four times daily.
Unlike cyclosporine and lifitegrast, perfluorohexyloctane does not primarily suppress ocular inflammation. Unlike artificial tears, it is not intended to provide only temporary aqueous lubrication. The product spreads across the ocular surface and reduces tear evaporation by interacting with the lipid layer of the tear film.
The FDA approved Miebo under New Drug Application 217174 on October 18, 2023. The approved indication is the treatment of the signs and symptoms of dry eye disease associated with meibomian gland dysfunction (U.S. Food and Drug Administration [FDA], 2023).
What clinical data support Miebo?
The pivotal efficacy program included the GOBI and MOJAVE Phase 3 trials. The studies evaluated patients with dry eye disease associated with meibomian gland dysfunction and compared perfluorohexyloctane with a control vehicle.
The principal efficacy measures included:
- Change in total corneal fluorescein staining.
- Change in eye dryness severity.
- Improvement in signs and symptoms associated with tear evaporation.
The clinical positioning is important commercially. Miebo is directed at evaporative dry eye and meibomian gland dysfunction, a segment that is often underdiagnosed or treated initially with over-the-counter products.
What is the FDA regulatory status and exclusivity timeline for perfluorohexyloctane?
Miebo is FDA-approved and commercialized in the United States by Bausch + Lomb. The product is not a biologic, so biosimilar pathways do not apply. Future competition would come through an abbreviated new drug application, a 505(b)(2) application, or a competing branded product.
| Regulatory event |
Date or status |
| FDA approval |
October 18, 2023 |
| NDA |
217174 |
| Approved indication |
Dry eye disease associated with meibomian gland dysfunction |
| Dosage form |
Ophthalmic solution |
| Sponsor and marketer |
Bausch + Lomb |
| Active ingredient |
Perfluorohexyloctane |
| Biosimilar exposure |
Not applicable |
| Likely first commercial generic pathway |
ANDA or 505(b)(2) |
If FDA granted five-year new chemical entity exclusivity, the principal statutory exclusivity period would extend into October 2028. The practical generic-entry date could be later because of Orange Book-listed patents, patent litigation, settlements, pediatric exclusivity or a successful patent-term extension.
The NCE question is commercially material. A five-year NCE period blocks an ANDA that relies on Miebo’s full FDA approval during the exclusivity period, although a 505(b)(2) pathway may raise separate regulatory and patent issues depending on the product and proposed labeling.
What patents protect perfluorohexyloctane and Miebo?
Miebo’s patent estate is expected to rely on composition, ophthalmic formulation, use and manufacturing protection rather than on a broad method-of-treatment claim alone.
The relevant patent categories include:
| Patent category |
Commercial role |
| Perfluorohexyloctane composition patents |
Protect the active pharmaceutical substance and defined chemical formulations |
| Ophthalmic formulation patents |
Protect concentration, purity, packaging, excipients and product specifications |
| Method-of-use patents |
Cover treatment of dry eye disease, meibomian gland dysfunction and tear evaporation |
| Manufacturing patents |
Protect synthesis, purification and control of fluorinated compounds |
| Device and container patents |
May cover bottle, dropper and delivery characteristics |
Publicly available patent disclosures indicate protection extending beyond the 2023 launch period and into the late 2030s or early 2040s for certain patent families. The effective end date depends on patent-family continuity, terminal disclaimers, patent-term adjustment, patent-term extension and the precise claims listed in the FDA Orange Book.
The strongest commercial claims are likely to be those that combine perfluorohexyloctane with ophthalmic use and product-specific formulation limitations. A generic manufacturer could attempt to design around formulation claims while still challenging the active ingredient, method-of-use claims or listed patents.
What is the Orange Book status of Miebo?
Miebo’s Orange Book position is central to generic-entry analysis. An Orange Book-listed patent can trigger a Paragraph IV notice and patent litigation after an ANDA filer certifies that the patent is invalid, unenforceable or not infringed.
The relevant legal questions are:
- Which patents are listed for NDA 217174?
- What are the expiration dates shown in the Orange Book?
- Do the listed patents cover the active ingredient, formulation, method of use or device?
- Has any patent received patent-term extension?
- Has Bausch + Lomb sued an ANDA filer within the statutory 45-day period?
FDA approval alone does not establish the commercial launch date for a generic. A first-filer may receive 180-day exclusivity, a patent settlement may delay entry, or a court decision may invalidate the relevant claims.
When does perfluorohexyloctane lose exclusivity?
The earliest realistic loss of regulatory protection is likely to be governed by the later of statutory exclusivity and enforceable patent rights.
Regulatory exclusivity
The October 2023 approval creates a potential five-year NCE protection period through October 2028. If that protection applies, an ANDA relying on Miebo’s approval could not receive approval before the end of that period.
Patent protection
The strongest patent protection appears to extend materially beyond 2028. The commercial loss-of-exclusivity window could therefore fall in the late 2030s rather than immediately after the end of NCE exclusivity.
The risk is not binary. A generic company can challenge patents before their expiration. A Paragraph IV certification could produce litigation years before the patent’s nominal expiry date. A successful invalidity or non-infringement ruling would accelerate competition.
Which companies are challenging Miebo?
No widely reported commercial generic launch has been established for perfluorohexyloctane as of the latest publicly available regulatory and company disclosures. The market is therefore still controlled by Bausch + Lomb.
Potential challengers include:
- Large generic ophthalmic manufacturers with sterile topical manufacturing capacity.
- Specialty generic companies active in dry eye products.
- Contract development and manufacturing organizations with fluorinated-compound capabilities.
- Branded ophthalmic companies pursuing 505(b)(2) products.
- International manufacturers seeking to enter markets outside the United States.
A future ANDA applicant would need to address sterility, container closure, drop uniformity, chemical purity, impurity control and formulation equivalence. Those requirements may reduce the number of credible challengers compared with standard aqueous ophthalmic products.
How strong is the patent estate for Miebo?
Miebo’s patent estate is commercially stronger than a single use patent but weaker than a fully protected product with broad composition, formulation, manufacturing and device claims that all expire at different times.
Strengths
- The product has a differentiated active ingredient.
- The FDA-approved formulation is linked to a specific therapeutic mechanism.
- Sterile ophthalmic manufacturing creates technical barriers.
- Method-of-use protection may complicate a label-scrubbing strategy.
- The product targets a defined disease mechanism rather than a general lubricant market.
Vulnerabilities
- A generic may challenge claim breadth around formulation and concentration.
- Perfluorohexyloctane is a small molecule, not a biologic, so the technical entry barrier is lower than for monoclonal antibodies.
- A successful Paragraph IV challenge could compress the protected revenue period.
- Physicians may prescribe competing products for the same dry-eye population even without direct substitution.
- Over-the-counter products can limit pricing power.
The estate is strongest if the core formulation claims survive validity and written-description challenges and if the Orange Book listings cover the commercially necessary product characteristics.
What is the Miebo financial trajectory?
Miebo launched in the fourth quarter of 2023. Bausch + Lomb reported an initial commercial contribution during the launch quarter, followed by a substantial increase in 2024 as the company expanded physician education, payer access and specialty-pharmacy distribution.
Public company reporting places Miebo’s 2024 revenue in the high tens to low hundreds of millions of dollars, depending on the reporting period and classification used in company disclosures. The product moved from launch-stage revenue to a meaningful contributor within Bausch + Lomb’s prescription ophthalmology portfolio.
| Financial phase |
Primary commercial characteristics |
| Q4 2023 launch |
Initial prescriptions, sampling and market-access buildout |
| 2024 scale-up |
Increased physician adoption and broader reimbursement |
| 2025 to 2027 potential |
Expansion within meibomian gland dysfunction and repeat-refill growth |
| Post-2028 |
Greater sensitivity to Paragraph IV activity and patent litigation |
| Late 2030s onward |
Potential generic or competing-product pressure, subject to patent outcomes |
Revenue growth should be evaluated against net price, not prescription volume alone. Miebo’s gross sales can be reduced by commercial rebates, government discounts, specialty-pharmacy fees, copay assistance and product returns.
The product’s long-term value depends on refill persistence. Dry eye is chronic, and a patient who remains on therapy can generate recurring revenue. Four-times-daily dosing and out-of-pocket cost may reduce persistence relative to less frequent regimens or lower-cost artificial tears.
What is the commercial price and reimbursement outlook?
Miebo entered a crowded market with a specialty prescription price materially above most over-the-counter lubricants. The economic case depends on insurance coverage and the perceived clinical value of treating meibomian gland dysfunction rather than repeatedly managing symptoms with artificial tears.
Key reimbursement variables include:
- Tier placement on commercial formularies.
- Prior authorization requirements.
- Step therapy through artificial tears or generic cyclosporine.
- Copay-card eligibility.
- Medicare Part D coverage.
- Employer-sponsored benefit design.
- Specialty-pharmacy dispensing requirements.
Bausch + Lomb has an incentive to invest in access programs because early formulary restrictions can reduce new-patient starts and increase discontinuation. The company also must balance volume growth against gross-to-net erosion.
How does Miebo compare with Restasis, Xiidra and Tyrvaya?
| Product |
Active ingredient |
Primary mechanism |
Main competitive position |
| Miebo |
Perfluorohexyloctane |
Reduces tear evaporation |
Meibomian gland dysfunction and evaporative dry eye |
| Restasis |
Cyclosporine |
Immunomodulatory, increases tear production over time |
Established chronic dry-eye therapy with generic competition |
| Xiidra |
Lifitegrast |
LFA-1 antagonist, reduces inflammation |
Prescription anti-inflammatory therapy |
| Tyrvaya |
Varenicline nasal spray |
Stimulates trigeminal pathway and natural tear production |
Non-ocular delivery and novel administration |
| Artificial tears |
Various lubricants |
Temporary lubrication |
Low-cost first-line treatment |
Miebo’s differentiation is mechanistic. It can be prescribed for patients whose dominant problem is tear-film evaporation and lipid-layer dysfunction. That differentiation supports premium pricing but limits the product to physicians who identify and treat the relevant disease subtype.
Restasis and Xiidra have broader familiarity and established prescribing habits. Their generic or authorized-generic competition can pressure payer budgets and make formulary access more difficult for Miebo.
What manufacturing and intellectual-property barriers affect entry?
Perfluorohexyloctane is a fluorinated small molecule with demanding purity and formulation requirements. Commercial manufacturing must control:
- Residual impurities.
- Batch-to-batch chemical consistency.
- Sterility and particulate levels.
- Container closure integrity.
- Drop size and dosing uniformity.
- Stability across the approved shelf life.
- Compatibility with ophthalmic packaging.
The active ingredient’s volatility, low water solubility and physical properties can create development challenges for an ANDA applicant. A generic manufacturer would also need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements applicable to the product.
Manufacturing barriers are meaningful but unlikely to be permanent. Once a capable supplier validates the active ingredient and sterile fill-finish process, those barriers can become manageable. The more durable protection is likely to come from the combination of regulatory requirements, patent claims and clinical-use positioning.
What patent litigation and settlement risks exist?
A future Paragraph IV filing could produce litigation under the Hatch-Waxman framework. The expected sequence would be:
- ANDA filing with Paragraph IV certification.
- Notice to Bausch + Lomb and relevant patent holders.
- Patent suit within 45 days.
- Potential 30-month stay of FDA approval.
- District-court judgment or settlement.
- Possible appeal and launch under an at-risk strategy.
Settlement terms could include a licensed-entry date, a launch date tied to patent expiry, supply arrangements or restrictions on an authorized generic. No widely reported final settlement has defined Miebo’s generic-entry date in the public record covered here.
What licensing deals affect perfluorohexyloctane?
Novaliq developed perfluorohexyloctane, while Bausch + Lomb obtained commercial rights for Miebo in the United States and Canada under a licensing arrangement announced in 2020. The agreement included an upfront payment, milestone payments and royalties tied to commercialization.
The license gives Bausch + Lomb access to an asset that fits its ophthalmology portfolio without requiring internal discovery of the active ingredient. Novaliq retains economic exposure through milestone and royalty structures, while Bausch + Lomb carries launch, manufacturing, market-access and commercial execution risk.
The economics of the license reduce Bausch + Lomb’s net contribution margin relative to an internally owned product. They also make peak sales and duration of exclusivity important to both parties.
What revenue exposure does Miebo create for Bausch + Lomb?
Miebo is not yet comparable in scale with Bausch + Lomb’s largest established products, but it is strategically important because it is a newer prescription asset with a potentially long growth runway.
Revenue exposure is concentrated in:
- Continued expansion of the dry-eye prescription market.
- Diagnosis rates for meibomian gland dysfunction.
- Repeat-refill persistence.
- Payer coverage.
- Competitive launches.
- Patent litigation outcomes.
- Physician willingness to pay for a non-anti-inflammatory therapy.
A successful expansion could make Miebo a meaningful specialty-ophthalmology franchise. A weaker outcome would result if physicians use it mainly after failure of cheaper therapies or if reimbursement limits access.
What generic launch scenarios exist for Miebo?
| Scenario |
Timing |
Commercial effect |
| No early Paragraph IV challenge |
After core patents expire |
Gradual erosion following standard generic entry |
| Paragraph IV challenge defeated |
After litigation |
Bausch + Lomb retains protection, but legal costs rise |
| Settlement with delayed entry |
Agreed future date |
Predictable erosion date and possible controlled competition |
| Patent invalidation or non-infringement |
Before nominal expiry |
Rapid price and volume pressure |
| 505(b)(2) competition |
Before full generic entry |
Possible targeted competition with differentiated labeling or formulation |
An authorized generic, if launched by or with Bausch + Lomb, could preserve some volume while reducing third-party generic penetration. The economic effect would depend on royalty obligations, transfer pricing and the structure of any settlement.
How does the global market affect perfluorohexyloctane?
United States revenue is the principal commercial driver because Miebo received its first major approval there and Bausch + Lomb has a large ophthalmology presence. International expansion can extend the product’s commercial life, but pricing and reimbursement differ significantly by country.
Geographic risks include:
- Delayed regulatory review.
- Local patent enforcement standards.
- Reference-pricing systems.
- National reimbursement restrictions.
- Different diagnostic practices for meibomian gland dysfunction.
- Local manufacturing or supply requirements.
International success is more likely in markets with high private ophthalmology spending and strong prescription access. Lower-price public systems may require evidence of cost-effectiveness before broad reimbursement.
Key Takeaways
- Perfluorohexyloctane is the active ingredient in Miebo, FDA-approved in October 2023 for dry eye disease associated with meibomian gland dysfunction.
- Miebo competes through a tear-evaporation mechanism that differs from Restasis, Xiidra, Tyrvaya and artificial tears.
- Bausch + Lomb’s commercial rights originated in a 2020 license from Novaliq.
- The product entered the market in late 2023 and generated materially higher revenue during 2024 as access and physician adoption expanded.
- Potential five-year NCE exclusivity could protect the product into October 2028, while patent protection may extend into the late 2030s or early 2040s for relevant claims.
- Generic risk will depend on Orange Book listings, Paragraph IV certifications, patent litigation and settlement terms.
- Manufacturing is more complex than for conventional aqueous eye drops but remains potentially accessible to experienced generic ophthalmic manufacturers.
- Long-term value depends on repeat use, payer coverage and the ability to establish meibomian gland dysfunction as a distinct treatment market.
FAQs
Is perfluorohexyloctane the same as Miebo?
Yes. Perfluorohexyloctane is the active ingredient in Miebo, the branded ophthalmic solution commercialized by Bausch + Lomb.
Is Miebo a biologic or eligible for biosimilar competition?
No. Miebo is a small-molecule ophthalmic drug. Competition would normally arise through an ANDA or potentially a 505(b)(2) application, not a biosimilar application.
Does Miebo treat inflammation like Restasis or Xiidra?
No. Miebo is designed primarily to reduce tear evaporation associated with meibomian gland dysfunction. Restasis and Xiidra are anti-inflammatory prescription therapies.
Can a generic manufacturer copy Miebo after FDA exclusivity expires?
Not automatically. The manufacturer must satisfy FDA requirements and address any Orange Book-listed patents. A Paragraph IV challenge could trigger litigation and delay approval or launch.
What is the main investment risk for Miebo?
The main risks are slower-than-expected physician adoption, restrictive reimbursement, low refill persistence, competition from established dry-eye products and an early successful patent challenge.
References
- Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Bausch + Lomb Corporation. (2020). Bausch + Lomb enters into exclusive licensing agreement with Novaliq for NOV03 in the United States and Canada.
- U.S. Food and Drug Administration. (2023). FDA approves new treatment for dry eye disease.
- U.S. Food and Drug Administration. (2023). Miebo prescribing information. NDA 217174.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- Novaliq GmbH. (2023). Miebo clinical development and regulatory information.
